ALK(SZ:002940) Zhi Tong Cai Jing·2025-10-19 08:20Core Viewpoint - The company has noted an increase in market interest regarding its innovative drug business, with only one project currently in development, ALK-N001, which is in Phase I clinical trials [1] Group 1: Innovative Drug Projects - The company is currently developing one innovative drug project, ALK-N001, which is still in Phase I clinical trials as of the date of this announcement [1] - A strategic cooperation agreement for the ALK-N002 project was signed on August 26, 2025, with Aifei (Shanghai) Biopharmaceutical Technology Co., Ltd. and Shanghai Qinhuali Biopharmaceutical Technology Co., Ltd. [1] - The strategic cooperation agreement has been approved by the company's shareholders, and Aifei Biopharmaceutical and Qinhuali are still undergoing internal approval processes [1]